United Kingdom In Vitro Diagnostics Market By Product (Instrument, Reagent, Other Products), By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, Other Types), By Usability (Disposable In Vitro Diagnostics Devices, Reusable In vitro Diagnostics Devices), By Application (Infectious Disease, Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, Others),
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom In Vitro Diagnostics Market By Product (Instrument, Reagent, Other Products), By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, Other Types), By Usability (Disposable In Vitro Diagnostics Devices, Reusable In vitro Diagnostics Devices), By Application (Infectious Disease, Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, Others),
The United Kingdom In Vitro Diagnostics Market is anticipated to grow significantly in the projected period, 2024-2028. The United Kingdom in vitro diagnostics market has experienced steady growth over the years, driven by factors such as an aging population, rising chronic diseases, and a focus on early detection and preventive care. The market encompasses a wide range of tests and technologies, including clinical chemistry, immunochemistry, molecular diagnostics, point-of-care testing, hematology, and microbiology, among others.
Testing carried out on human bodily tissue or blood samples is known as in vitro diagnostics (IVD). In vitro diagnostics can be used to monitor a person's overall health, diagnose diseases or other disorders, and help treat, prevent, or cure illnesses. Precision medicine may also make use of in vitro diagnostics to pinpoint patients who will likely benefit from particular medications or treatments, leading to the growth of the United Kingdom In Vitro Diagnostics Market. Next-generation sequencing tests, which scan a person's DNA to find genetic changes, can be a part of these in vitro diagnostics.
Rapid advancements in diagnostic technologies, such as next-generation sequencing, digital pathology, and lab automation, will revolutionize the in vitro diagnostics landscape. These innovations will enable faster and more accurate diagnoses, leading to improved patient outcomes and cost-effective healthcare, hence augmenting the growth of the United Kingdom In Vitro Diagnostics Market.
According to the Office for National Statistics, the cost of healthcare in the UK was estimated to be around USD350.83 billion in 2022, a rise in nominal terms of 0.7% over 2021
In-vitro diagnostics is in high demand due to the need for early diagnosis and monitoring of various disorders utilizing imaging technologies for better disease management and treatment planning. This has resulted in a boom in the in-vitro diagnostics market in the United Kingdom.
According to the Office of National Statistics, almost 11 million persons, or 18.6% of the total population, were 65 years of age or older in 2021, compared to 16.4% at the time of the previous census in 2011
Recent Advancements in Pharmacogenomics Drive United Kingdom's In Vitro Diagnostics Market
In the United Kingdom, recent advancements in pharmacogenomics have been instrumental in driving the growth of the in vitro diagnostics (IVD) market. Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, has revolutionized the field of healthcare. By combining genetics and genomics with traditional medicine, pharmacogenomics provides personalized treatment options that are tailored to a patient's genetic profile. This has led to the expansion of the United Kingdom In Vitro Diagnostics Market.
The National Health Service (NHS) in the United Kingdom has recognized the potential of pharmacogenomics and has started implementing guidelines for its incorporation into clinical practice. These guidelines help healthcare professionals make informed decisions based on a patient's genetic information, improving treatment outcomes and patient safety. Pharmacogenomics will be included in the ordinary National Health Service practice to provide patients with safer and more effective treatments, and to prevent wasting time and money on procedures that may be unsuccessful or even hazardous.
The development of high-throughput DNA sequencing and genotyping technologies has made it possible to rapidly and cost-effectively analyze an individual's genetic profile. These advancements have facilitated the integration of pharmacogenomics into routine clinical practice, thereby augmenting the growth of the United Kingdom In Vitro Diagnostics Market.
Rising Geriatric Population Revolutionize the United Kingdom In Vitro Diagnostics Market
According to the House of Commons Library, the older population in the United Kingdom will increase, accounting for 24% of the total population (17.4 million people) by 2043. The percentage of people aged 75 and older is anticipated to increase from 8% in 2018 to 13% in 2043, while the percentage of people aged 85 and older is anticipated to increase from 2% to 4%.
Prevalence of Infectious Diseases
Infectious diseases pose a significant burden on public health systems and economies worldwide. The United Kingdom has faced outbreaks of diseases such as influenza, tuberculosis, hepatitis, sexually transmitted infections, and, recently, the COVID-19 pandemic. These outbreaks have highlighted the importance of rapid and accurate diagnostics for effective disease control and management. According to the Office of National Statistics 2019, allergy was the most frequently reported chronic health condition in both men and women (30.4% and 36.0%, respectively), followed by high blood pressure, low back disorder, and depression as the four most prevalent chronic conditions in the United Kingdom. In addition to having a negative impact on people's quality of life, chronic diseases place a heavy financial burden on the healthcare system. To facilitate early and accurate diagnosis of chronic diseases, monitor disease progression, and inform treatment choices, there has been an increasing demand for advanced in-vitro diagnostic technologies in the United Kingdom. This has caused the market for in-vitro diagnostics to grow in the United Kingdom, where a variety of modalities are being used. The growing understanding of the value of early disease detection and prevention is another factor influencing the growth of the in-vitro diagnostics market in the United Kingdom.
Recent Developments
- In January 2023, the majority of in-vitro diagnostic (IVD) devices will be evaluated by UL International UK Ltd, according to the Medicines and Healthcare products Regulatory Agency (MHRA). This will boost the United Kingdom's capacity to handle conformity assessments and ensure that safe and effective IVDs are available to UK citizens.
- In July 2022, Siemens Healthineers unveiled The Atellica CI 1900 Analyzer, a clinical chemistry and immunoassay testing system. It is a lower volume variant of their currently marketed Atellica clinical chemistry and immunoassay testing solution. The system has the ability to perform over 25,000 immunoassay tests annually and over 250,000 clinical chemistry tests annually. According to Siemens Healthineers, the new analyzer can be used as a stand-alone system in hub-and-spoke configurations connected to integrated delivery networks.
Mergers and Collaborations
- In March 2023, Agilent and Sophia Genetics collaborated to develop a cancer analysis solution. The partnership will integrate Agilent's SureSelect Cancer CGP Assay Kit and the SOPHiA DDM Platform, enabling clinical researchers to accurately identify a variety of biomarkers. This integration will reduce the possibility of omitting important information in cancer sample analysis.
Market Segmentation
The United Kingdom In Vitro Diagnostics Market is segmented by Product, Test Type, Usability, Application, End User, Region, and Competitive Landscape. Regarding Product, the market is divided into Instrument, Reagent, and Other Products. Test Types include Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, and Other Types. Usability category consist of Disposable In Vitro Diagnostics Devices and Reusable In vitro Diagnostics Devices. The Application segment includes Infectious Disease, Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, and others. End Users are categorized as Diagnostic Laboratories, Hospitals & Clinics, and Others. The market is further segmented by region, including Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux UK, Becton Dickinson and Company, Danaher Corporation, Agilent Technologies, Inc., Sysmex UK Ltd, Siemens Healthineers, Charles River Laboratories, Bio-Rad Laboratories, Inc are some of the key players of United Kingdom In Vitro Diagnostics market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company shares, competitive landscape, growth factors, and trends |
| Segments covered | Product Test Type Usability Application End User Region |
| Country scope | Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands |
| Key companies profiled | F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux UK, Becton Dickinson and Company, Danaher Corporation, Agilent Technologies, Inc., Sysmex UK Ltd, Siemens Healthineers, Charles River Laboratories, Bio-Rad Laboratories |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy